In hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer, the dysregulation of the CDK4/6 pathway leads to uncontrolled cellular proliferation, which is central to disease progression. This evidence concerns the gene ERBB2 and breast cancer.